Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832082 | 0.93 | RAB9A (0.64) | RAB9AHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL29687812 | 0.93 | RAB9A (0.64) | RAB9AHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL8490672 | 0.86 | HPGD (0.64) | RAB9AHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL8007083 | 0.85 | RAB9A (0.82) | RAB9AHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL11608173 | 0.84 | RAB9A (0.64) | RAB9AHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL20169847 | 0.84 | SMN1; SMN2 (0.65) | RAB9AHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL7565913 | 0.82 | RAB9A (0.81) | RAB9AHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL699298 | 0.81 | HPGD (0.58) | RAB9AHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL7995030 | 0.81 | RAB9A (0.65) | RAB9AHPGDLMNASMN1; SMN2NPC1 | |
| SCHEMBL8076542 | 0.81 | RAB9A (0.65) | RAB9AHPGDLMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012040623-A2 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | RAB9A 1945/4885HPGD 87/4885LMNA 2278/4885 |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | RAB9A 1945/4885HPGD 87/4885LMNA 2278/4885 |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | MMP2, MMP1, GUSB | RAB9A 2233/4885HPGD 85/4885LMNA 1911/4885 |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | RAB9A 1945/4885HPGD 87/4885LMNA 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.